| |
Morgan & Finnegan is a leader in protecting the intellectual property of some of the world's leading pharmaceutical companies. We are regularly involved with patent protection in a great number of areas: analgesics, antibiotics, beta-blockers, cancer drugs, central nervous system depressants, sedatives, pioneering drugs and many more.
Our work has been shaped by one purpose: to enable our pharmaceutical clients to maximize the value of their patents, the first, critical step toward recouping the enormous costs of drug development. We help ensure that they build strategically solid portfolios and are well-positioned to negotiate cross-licensing and royalty agreements.
Our attorneys and Ph.D. scientific advisors work with pharmaceutical clients on every aspect of IP development, defense and asset maximization. Our clients work in a relentlessly global industry; we establish global patent strategies crafted to take into account widely differing business cultures and practices. Our opinion work is authoritative and of the highest quality, a dependable tool with which to help judge patent validity, infringement or enforceability. And in an industry subject to acute regulation, we keep clients apprised of the ever-evolving intricacies of federal legislation and often conflicting requirements of patent, regulatory and antitrust law.
The attorneys and scientific advisors in our pharmaceutical practice are well aware that keeping ahead of the curve, scientifically and commercially, is merely the price of entry here. We have experience with the wide range of available diagnostic tools, drug delivery systems such as transdermal patches, and medical devices such as angioplasty balloon catheters, syringes and suturing devices. We work with the world's leading research scientists, those who are active in the quest for effective treatments for AIDS, diabetes, cancer and other illnesses. Simply put, we have the technical expertise you would expect of us.
Representative recent matters include the successful opposition of European Patent EP 0896538B1 on behalf of Bristol-Meyers Squibb. The patent, which was revoked by the Opposition Division in Munich, was for a method of treating diabetes by inhibiting an enzyme that attacks the molecule that triggers the production of insulin. This technique is among the newest areas of drug development being pursued by several major pharmaceutical companies, including Bristol-Meyers Squibb. The Hans-Ulrich Demuth patent, which was owned by Probiodrug AG of Halle, Germany, had stood as a major impediment in Europe. We also defended Novo Nordisk in a patent infringement action involving recombinant human growth hormone (hGH) and insulin.
|
Printable Version
